Clinical reference Biomarker Directory
Back to directory

Interleukin 1-Alpha

Emerging

IL-1α is a pro-inflammatory alarm cytokine, indirectly blocked by anakinra alongside its better-known relative IL-1β.

Also known as IL-1 alpha interleukin-1 alpha
In plain language

IL-1 alpha is closely related to IL-1 beta and helps trigger inflammation, especially as a signal from damaged cells. Most current anti-inflammatory drugs targeting this cytokine family work on the shared receptor rather than singling out this particular one.

Biomarker & context

Interleukin 1-alpha (IL-1α) is a pro-inflammatory cytokine related to IL-1 beta (discussed elsewhere in this set), involved in early inflammatory signaling and tissue damage response.

What it indicates

IL-1α plays a role in early inflammatory signaling, particularly as an alarm signal released from damaged or dying cells, though it's less commonly targeted directly by current biologic therapies compared to its better-known relative, IL-1 beta.

Diagnosis & clinical testing

IL-1α is not routinely measured as a standard clinical diagnostic test; most clinical drug development in this cytokine family has focused on IL-1 beta or broader IL-1 receptor blockade (anakinra, which blocks both IL-1α and IL-1β signaling) rather than IL-1α specifically.

Guiding treatment

Anakinra, which blocks the shared IL-1 receptor, provides indirect IL-1α blockade alongside its IL-1β effects in treating autoinflammatory conditions, though no therapy specifically and selectively targets IL-1α alone in current clinical use.

Clinical significance

Less directly targeted by current biologic therapies compared to IL-1β, which has more dedicated therapeutic development.

References
  1. General immunology reference literature on IL-1 alpha and IL-1 receptor blockade in autoinflammatory disease.